Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Replagal

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

Sanofi reception

Translate Bio, Sanofi’s COVID-19 vaccine proves promising in animal studies

Vaccine was able to induce neutralising antibodies and T-cell responses

- PMLiVE

Takeda to sell Japan consumer health unit for $2.3bn

Deal helps to reduce debt accrued from Shire takeover

- PMLiVE

NICE recommends Roche’s Polivy for B-cell lymphoma

Cost-effectiveness agency approves drug following initial rejection earlier this year

Sanofi reception

Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma

French drugmaker will gain access to a portfolio of BTK inhibitors

Sanofi reception

Sanofi faces manslaughter allegations in France over Depakine deaths

Charges relate to deaths of four babies whose mothers took anti-epileptic drug during pregnancy

- PMLiVE

US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine

Both companies are also in talks with EU for access to candidate

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

NICE recommends Astellas’ Xospata for NHS use

Cost-effectiveness watchdog backtracks on previous rejection

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

Sanofi reception

Sanofi doses first patient in global Kevzara COVID-19 trial

Sanofi is leading trials outside the US while Regeneron is leading US trials

- PMLiVE

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

Monthly meeting held remotely for the first time due to COVID-19 pandemic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links